» Articles » PMID: 8360969

Comparison of Survival Probabilities for Dialysis Patients Vs Cadaveric Renal Transplant Recipients

Overview
Journal JAMA
Specialty General Medicine
Date 1993 Sep 15
PMID 8360969
Citations 169
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To compare mortality risk among cadaveric renal transplant recipients vs transplant candidates on dialysis in the cyclosporine era.

Setting: Patient mortality risk was analyzed by treatment modality for a completed statewide patient population.

Patients: All Michigan residents younger than age 65 years who started endstage renal disease (ESRD) therapy between January 1, 1984, and December 31, 1989, were included. Patients were followed up from ESRD onset (n = 5020), to wait-listing for renal transplant (n = 1569), to receiving a cadaveric first transplant (n = 799), and to December 31, 1989.

Main Outcome Measure: Mortality rates.

Results: Using a time-dependent variable based on the waiting time from date of wait-listing to transplantation and adjusting for age, sex, race, and primary cause of ESRD, the relative risk (RR) of dying was increased early after transplantation and then decreased to a beneficial long-term effect, given survival to 365 days after transplantation (RR, 0.36; P < .001). This lower long-term risk was most pronounced (RR, 0.25) among diabetic transplant recipients compared with diabetic wait-listed dialysis patients (P < .001) and not observed among patients with glomerulonephritis as cause of ESRD (P > .05). Overall, the estimated times from transplantation to equal mortality risk was 117 +/- 28 days and to equal cumulative mortality was 325 +/- 91 days.

Conclusions: The overall mortality risk following renal transplantation was initially increased, but there was a long-term survival benefit compared with similar patients on dialysis. These analyses allow improved description of comparative mortality risks for dialysis and transplant patients and allow advising patients regarding comparative survival outcomes.

Citing Articles

Trends in Precision Medicine and Pharmacogenetics as an Adjuvant in Establishing a Correct Immunosuppressive Therapy for Kidney Transplant: An Up-to-Date Historical Overview.

Belardi R, Pacifici F, Baldetti M, Velocci S, Minieri M, Pieri M Int J Mol Sci. 2025; 26(5).

PMID: 40076585 PMC: 11900248. DOI: 10.3390/ijms26051960.


Kidney Transplant Fast Track and Likelihood of Waitlisting and Transplant: A Nonrandomized Clinical Trial.

Myaskovsky L, Leyva Y, Puttarajappa C, Kalaria A, Ng Y, Velez-Bermudez M JAMA Intern Med. 2025; .

PMID: 40063052 PMC: 11894542. DOI: 10.1001/jamainternmed.2025.0043.


Impact of public versus non public insurance on hispanic kidney transplant outcomes using UNOS database.

Thongprayoon C, Garcia Valencia O, Jadlowiec C, Mao S, Mao M, Leeaphorn N Sci Rep. 2025; 15(1):4879.

PMID: 39929971 PMC: 11811044. DOI: 10.1038/s41598-025-88672-3.


Long-term Double-J stenting is superior to short-term Single-J stenting in kidney transplantation.

Oudmaijer C, Muller K, van Straalen E, Minnee R, Kimenai D, Reinders M PLoS One. 2025; 20(1):e0317991.

PMID: 39883793 PMC: 11781732. DOI: 10.1371/journal.pone.0317991.


Neuroimaging Augments DCD-N Score in Predicting Time from Withdrawal of Life-Sustaining Measures to Death Among Potential Organ Donors.

Kramer A, Couillard P, Doig C, Kromm J Neurocrit Care. 2025; .

PMID: 39776350 DOI: 10.1007/s12028-024-02204-x.